Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Niacin
Drug ID BADD_D01559
Description Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Indications and Usage For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
Marketing Status Prescription; Discontinued
ATC Code C04AC01; C10AD02
DrugBank ID DB00627
KEGG ID D00049
MeSH ID D009525
PubChem ID 938
TTD Drug ID Not Available
NDC Product Code 71740-201; 51407-268; 71741-020; 62175-322; 59746-380; 0074-3274; 25441-0095; 47335-613; 65162-323; 62331-016; 59746-387; 71741-047; 50268-584; 68180-222; 47335-614; 51407-267; 59746-381; 0074-3275; 59651-019; 63629-7193; 72919-420; 59651-018; 59651-020; 71740-001; 62175-320; 0074-3265; 68180-221; 33342-189; 51552-0559; 68180-223; 33342-187; 62704-0027; 47335-539; 65162-322; 65372-1194; 65162-321
Synonyms Niacin | Nicotinic Acid | 3-Pyridinecarboxylic Acid | 3 Pyridinecarboxylic Acid | Niacin Lithium Salt, Hemihydrate | Niacin Potassium Salt | Potassium Salt, Niacin | Niacin Sodium Salt | Sodium Salt, Niacin | Niacin Tartrate | Tartrate, Niacin | Niacin Copper (2+) Salt | Niacin Hydrochloride | Hydrochloride, Niacin | Niacin Iron (2+) Salt | Niacin Tosylate | Tosylate, Niacin | Niacin Zinc Salt | Nicamin | Nico-400 | Nico 400 | Nico400 | Nicobid | Nicocap | Nicolar | Nicotinate | Wampocap | Enduracin | Induracin | Niacin Calcium Salt | Lithium Nicotinate | Nicotinate, Lithium | Niacin Aluminum Salt | Aluminum Salt, Niacin | Niacin Ammonium Salt | Niacin Lithium Salt | Niacin Cobalt (2+) Salt | Niacin Magnesium Salt | Niacin Manganese (2+) Salt
Chemical Information
Molecular Formula C6H5NO2
CAS Registry Number 59-67-6
SMILES C1=CC(=CN=C1)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Glucose tolerance decreased13.02.02.004--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Hallucination19.10.02.0020.000724%
Headache17.14.01.0010.002894%
Heart rate increased13.14.04.0020.000724%Not Available
Hepatitis09.01.07.0040.001085%Not Available
Hepatotoxicity09.01.07.009; 12.03.01.0080.000724%Not Available
High density lipoprotein decreased13.12.01.0030.000724%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.0030.005427%
Hypertension24.08.02.0010.000724%
Hypotension24.06.03.002--
Insomnia17.15.03.002; 19.02.01.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Laryngospasm22.04.02.002--
Liver disorder09.01.08.0010.000724%Not Available
Loss of consciousness17.02.04.0040.001085%Not Available
Macular oedema06.04.06.005--Not Available
Maculopathy06.09.03.0070.000724%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Muscle spasms15.05.03.0040.000724%
Myalgia15.05.02.0010.001809%
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuropathy peripheral17.09.03.0030.000724%Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Oesophagitis07.08.05.0010.000724%
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages